Drug Profile
Rotavirus vaccine - GlaxoSmithKline
Alternative Names: 89-12; GSK 444563; GSK Biologicals' liquid human rotavirus vaccine 444563; GSK rotavirus vaccine 444563; GSK vaccine 444563; HRV Liquid - GlaxoSmithKline; HRV Lyophilized - GlaxoSmithKline; Liq PCV-free HRV; RIX-4414; Rotarix; Rotavirus vaccine - AVANT Immunotherapeutics/GlaxoSmithKline; Rotavirus vaccine 444563 - GlaxoSmithKline; SB-444563Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics; Cincinnati Childrens Hospital Medical Center
- Developer GlaxoSmithKline; GSK; Japan Vaccine
- Class Attenuated vaccines; Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rotavirus infections
- Phase III Gastroenteritis
Most Recent Events
- 01 Sep 2023 Phase-III clinical trials in Gastroenteritis (In infants, In volunteers) in China (PO) (NCT06025695)
- 08 Jun 2023 GlaxoSmithKline initiated a phase III trial (In volunteers, In adolescents, In children, In infants, In neonates) in China (EudraCT2022-000708-36)
- 17 May 2023 GlaxoSmithKline plans a phase III trial (In volunteers, In infants, In neonates, Prevention) (PO, Suspension) in China (EudraCT2020-000972-38)